ANTITUMOUR AGENTS FROM MARINE MICROALGAE

来自海洋微藻的抗肿瘤剂

基本信息

批准号：
6203315
负责人：
YUZURU SHIMIZU
金额：
$ 15.64万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
起止时间：
1999-09-24 至 2000-08-31
项目状态：
已结题

项目摘要

The long-term objective of this part of the proposal is to develop antitumor, antiviral, an antimicrobial drugs from microalgal sources. The proposal is based on the recent findings of the occurrence of promising compounds in dinoflagellates and other microalgae. Anticipated compounds include polyethers, macrolides, other polyoxygenated compounds, cyclic peptides and depsipeptides. There are strong indications that many of the unique metabolites found in marine invertebrates are actually derived from microalgae. The applicant's group has lengthy experience in culturing microalgae and studying their secondary metabolites and is in possession of a vast collection of unexamined microalgal strains. Specifically, l. Free-living dinoflagellates, diatoms, algae in Chrysophyta, and other microalgae from both temperate and tropical waters, and some from freshwater, will be collected, cultured and screened for the bioactivity. 2. Organisms of the above classes symbiotic or associated with marine invertebrates and algae will be isolated, cultured and screened. 3. Active compounds will be isolated, and the structures of the purified compounds will be studied by physico-chemical methods including high field NMR, mass spectroscopy, and X-ray crystallography. Antitumor and antiviral assays and further development of drugs will be conducted by Bristol-Myers Squibb Co., but limited in-house cytotoxicity and antimicrobial tests will be performed as quick isolation guides.

这部分提案的长期目标是开发抗肿瘤、抗病毒、微藻来源的抗菌药物。该提案是基于最近发生的事件的调查结果甲藻和其他微藻中有前景的化合物。预期的化合物包括聚醚、大环内酯、其他多含氧化合物、环肽和缩酚肽。那里强有力的迹象表明，许多独特的代谢物存在于海洋无脊椎动物实际上源自微藻。这申请人团队在微藻培养方面拥有丰富的经验研究它们的次生代谢物并拥有大量未经检查的微藻菌株的收集。具体来说，湖自由生活的甲藻、硅藻、金藻门中的藻类，以及来自温带和热带水域的其他微藻，以及一些从淡水中收集、培养和筛选生物活性。 2. 与海洋共生或相关的上述类别的生物无脊椎动物和藻类将被分离、培养和筛选。 3. 分离出活性化合物，并得到其结构纯化的化合物将通过物理化学方法进行研究包括高场核磁共振、质谱和 X 射线晶体学。抗肿瘤和抗病毒测定以及进一步药物的开发将由百时美施贵宝公司进行，但有限的内部细胞毒性和抗菌测试将作为快速隔离指南执行。